Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum Alan J. KrakerCharles W. MooreWilliam L. Elliott Preclinical Studies Pages: 1 - 8
Cyclopentenyl cytosine: Interspecies predictions based on rodent plasma and urine kinetics Daniel S. ZaharkoJames A. KelleyNeil R. Hartman Preclinical Studies Pages: 9 - 17
Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137 Mina E. Holm JuulJohn M. DornishReidar Oftebro Preclinical Studies Pages: 19 - 28
Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines in vitro S. C. BarrancoB. WeintraubC. M. Townsend Jr. OriginalPaper Pages: 29 - 36
A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinum Kapil DhingraMoshe TalpazJordan U. Gutterman OriginalPaper Pages: 37 - 39
Crisnatol mesylate: Phase I dose escalation by extending infusion duration Elizabeth A. PoplinGuy G. ChabotLaurence H. Baker OriginalPaper Pages: 41 - 47
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma Stephen K. WilliamsonMilan Slavik OriginalPaper Pages: 49 - 52
Phase I–II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma S. R. PatelL. K. KvolsJ. S. Kovach OriginalPaper Pages: 53 - 57
A phase II study of taxol in patients with malignant melanoma Avi I. EinzigHoward HochsterThomas J. Smith OriginalPaper Pages: 59 - 64
Phase II study of amonafide (Nafidamide, NSC 308847) in advanced colorectal cancer Peter J. O'DwyerAnthony R. PaulRobert L. Comis Brief Report Pages: 65 - 67
Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma Hari M. DhingraWilliam K. MurphyWaun Ki Hong OriginalPaper Pages: 69 - 72
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma Ralph B. VanceJohn J. CrowleyFrederick R. Ahmann OriginalPaper Pages: 73 - 75
Phase II trial of menogaril in adenocarcinoma of the pancreas Thomas D. BrownPhyllis J. GoodmanJohn S. Macdonald OriginalPaper Pages: 77 - 78
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma J. SkillingsC. CrippsD. Walde OriginalPaper Pages: 79 - 82
Phase II study of 4 ′ -deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach George SomloJames DoroshowJames Raschko OriginalPaper Pages: 83 - 85
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer Daniel D. Von HoffStephanie J. GreenC. Kent Osborne OriginalPaper Pages: 87 - 88
Phase II clinical trial of 4′-O-Tetrahydropyranyl-Adriamycin (THP-Adriamycin) in recurrent squamous cell carcinoma of the head and neck Dong M. ShinAlan M. KramerWaun Ki Hong OriginalPaper Pages: 89 - 91
A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus Robert E. SlaytonJohn A. BlessingDaniel Clarke-Pearson OriginalPaper Pages: 93 - 94
Phase II study of pibenzimol in pancreatic cancer Eric H. KrautTom FlemingJohn MacDonald OriginalPaper Pages: 95 - 96
Phase II trial of N-methylformamide in patients with metastatic melanoma Omar EtonDean F. BajorinAlan N. Houghton OriginalPaper Pages: 97 - 100
Phase II trial of cisplatin and etoposide in patients with metastatic melanoma Omar EtonDean F. BajorinAlan N. Houghton OriginalPaper Pages: 101 - 103
Evaluation of fludarabine phosphate in malignant melanoma Julie A. KishKen KopeckyFranco M. Muggia OriginalPaper Pages: 105 - 108
A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix John H. MalfetanoJohn A. BlessingParviz Hanjani OriginalPaper Pages: 109 - 111
Phase II trial of echinomycin in advanced colorectal cancer Thomas D. BrownPhyllis J. GoodmanJohn S. Macdonald Brief Report Pages: 113 - 114
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics Daniel D. Von HoffJudith Turner OriginalPaper Pages: 115 - 122